| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and lowers the price target from $28 to ...
Leerink Partners analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from ...
WMT, INTU, GAP, SNDK, MRNA were the stocks seen trending on Thursday, Nov. 20, 2025.
Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business stra...
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2...
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing networkMore than $...